Table 1.
Characteristics and questionnaire responses of the patients in the SpA cohorta
| Characteristic | SpA patients (n = 609) |
|---|---|
| Age, mean ± SD years | 45 ± 11 |
| Female sex | 460 (76) |
| Treatment | |
| Biologic DMARDs | 482 (79) |
| NSAIDs only | 127 (21) |
| Combination NSAIDs and biologic DMARDs | 428 (70) |
| Modified their treatmentb | 276 (47) |
| Biologic DMARDsc | |
| No modification | 365 (76) |
| Stopped | 53 (11) |
| Extension of the interval between doses | 66 (14) |
| NSAIDsd | |
| Modification of NSAID intake | 217 (39) |
| Stopped | 156 (28) |
| Reduced intake | 61 (11) |
| Worsening of disease | 382 (63) |
| Infection onset | 88 (14) |
| Symptoms suspicious of COVID‐19 | 13 (2) |
| Self‐report of confirmed COVID‐19 infection | 18 (3) |
a
Except where indicated otherwise, values are the number (%). SpA = spondyloarthritis; COVID‐19 = coronavirus disease 2019.
b
Data available on 589 patients.
c
All patients treated with biologic disease‐modifying antirheumatic drugs (DMARDs) (n = 482).
d
All patients treated with nonsteroidal antiinflammatory drugs (NSAIDs) (n = 555).